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adenoviruses (CRAds)Abstract Background: Mesenchymal stem cells (MSCs) are recruited to the stroma of cancers. They
interact with cancer cells to promote invasion andmetastasis or to suppress tumor growth. The unique
tumor-homing capacity ofMSCsmakes thema promising vehicle to deliver various anticancer agents.
Aim: The aim of this study was to detect the possibility of using mesenchymal stem cells as a future
weapon against breast cancer.
Methods: PubMed, PubMed central, Springer andCochrane databases were searched using specified
terms.
Results: Literature search yielded 17manuscripts: seven ofwhich suggested the use ofMSCs in breast
cancer therapy, while six studies raised the possibility thatMSCsmay promote tumor growth and four
other studies assumed a dual role for MSCs.
Conclusions: The role of MSCs in breast cancer therapy is still debatable. We recommend future
research in thefieldofMSCs inAlexandriaUniversity as it is ourhope in thefight against breast cancer.
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2 H.A. Shakshouk, H. Rashwan1. Introduction
Breast cancer is the most common malignancy among females
throughout the world. Combined therapeutic modalities
including surgery, chemotherapy, radiotherapy, endocrine
and targeted therapies are the mainstay of treatment. How-
ever, they may lead to unsatisfactory outcomes, mainly due
to the difficulty in accessing tumor sites, the dispersed nature
of the disease and the toxicity of the treatment.1
MSCs were originally isolated from bone marrow, and later
from adipose tissues and many other organs. These cells are
capable of self-renewal and differentiation into bone, fat, or
cartilage cells under appropriate conditions.2
MSCs are often involved in tissue remodeling after injury
or chronic inflammation. Tumors resemble chronic wounds
or ‘‘wounds that never heal”.2 The recruited MSCs and their
derivative cancer-associated fibroblasts interact with cancer
cells to promote invasion and metastasis. On the other hand,
the unique tumor-homing capacity of MSCs renders them a
promising vehicle for adequate and specific delivery of various
anticancer agents.2
This article discusses the potential of using MSCs as a
weapon against breast cancer.
2. Methods
PubMed, PubMed central, Springer and Cochrane databases
were searched using specified terms. Key words used were mes-
enchymal stem cells, mesenchymal stem cells and breast can-
cer, breast cancer.
Inclusion criteria Publications on mesenchymal stem cells
were included in the study. Reference lists of reviews and
research articles were examined for relevant publications.
Exclusion criteria Case reports, letters, reviews without
original data, non-English language papers, abstracts, and
articles with incomplete data were excluded.
3. Results and discussion
Various studies have reported contradicting results as regards
the role of MSCs in breast cancer. While several studies sup-
port the growth promoting effects of MSCs, others suggest
that they act as tumor suppressive agents. A dose dependent
effect has been proposed to explain these varying roles; at
lower cell numbers (relative to the number of tumor cells)
human MSCs are more likely to inhibit tumor growth, whereas
at higher cell numbers they promote tumor growth.3 Alterna-
tive theories state that these varying roles might be related to
the presence of different subpopulations among MSCs, indi-
vidual variations in the physiological immune status of the
donors, and differences in MSC isolation and culture meth-
ods.4 Other mechanisms have been reported as well including
chemokine signaling, modulation of apoptosis, vascular sup-
port, and immune modulation.5
3.1. Suppression of tumor growth
The role of MSCs as tumor suppressors depends mainly on
their involvement in tissue remodeling after injury or chronic
inflammation. MSCs are recruited specifically to the tumor site
to form tumor stroma.2The avid tropism of MSCs to tumors, as well as their ability
to engraft, survive, and proliferate in the tumor architecture,
renders them prime cellular vehicles for the delivery of anti-
neoplastic therapy to both primary tumors and their
metastases.4
Brennen et al.1 demonstrated that MSCs engrafted in
tumors could act as stromal precursor cells and successfully
function as cellular vehicles for gene delivery and contribute
to the local production of biological agents.1
A number of approaches have been utilized in this regard.
For example the use of genetically modified MSCs to kill
malignant cells has shown positive results.6 (Fig. 1)4
Systemically-infused interferon beta (IFN-b) expressing bone
marrow-derived MSCs successfully reduced the growth of
human breast cancer cells from MDA-MB-231 line upon
engraftment into the tumor stroma.6
BALB/c murine MSCs home specifically to mouse 4T1 sites
and deliver murine IFN-b to the tumors sufficient to inhibit
breast cancer growth through inactivation of the Stat3 signal-
ing pathway. In addition, MSC/IFN-b/GFP treatment also
showed signs of an improvement in cell-mediated immunity
as indicated by the increased numbers of splenic mature
dendritic cells and decreased numbers of regulatory
T lymphocytes.7
Liu et al. studied the effects of hUMSCs/IL-18 (human
umbilical cord MSCs genetically modified with interleukin-18
gene) on the growth, migration and invasion of two breast can-
cer cell lines in vitro. The results showed that hUMSCs/IL-18,
but not hUMSCs, significantly inhibited the growth, migration
and invasion of human breast cancer cell lines MCF-7 and
HCC1937 in vitro. Flow cytometric analysis showed that
hUMSCs/IL-18 significantly increased the percentage of cells
in the G0/G1 phase but decreased that in the S and G2/M
phase.1
The second approach was the use of MSCs as intermediate
carriers for conditionally replicating adenovirus (CRADs) to
target metastatic breast cancer in vivo.8 Stoff-Khalili et al. con-
cluded that hMSCs may be an effective platform for targeted
delivery of CRAds to distant cancer sites such as metastatic
breast.
They investigated the in vivo anti-tumor activity of hMSC-
Ad5/3.CXCR4 (C-X-C chemokine receptor 4). Mice injected
with hMSC-Ad5/3.CXCR4 had significantly lower mean lung
weights than Ad5/3.CXCR4 treated or control untreated mice.
Thus, the tumor burden of breast cancer metastases in the
lungs was significantly less in animals treated with CRAd
loaded hMSCs than with the CRAd alone. Furthermore, treat-
ment with hMSC-Ad5/3.CXCR4 improved survival of mice
bearing breast cancer metastases in the lungs.8
MSCs were found to inhibit tumor growth through a vari-
ety of other mechanisms including secretion of paracrine fac-
tors. Ma et al.4 studied the effect of hUMSCs on cancer
stem cells in vitro. The results showed that hUCMSCs inhib-
ited the growth of breast cancer cell lines (MDA-MB-231
and MCF-7), and primary breast cancer stem cells (CSCs) in
a dose-dependent manner. The underlying mechanism is likely
related to cell cycle arrest and induction of tumor cell apopto-
sis.4 HUMSCs were also found to inhibit the development of
pulmonary metastases from breast adenocarcinoma MDA-
MB-231 cell line in vivo in mice. Long-term in vivo biolumines-
cence imaging of intravenously injected MSCs genetically
labeled with luc2 gene showed distribution of MSCs to the
Figure 1 MSC-based caner therapy. Several approaches have been applied using MSCs as a delivery system for anti-neoplastic agents.
These methods culminate in cancer cell killing through different mechanisms. Some of which include enhancing the host’s local immune
responses through MSC gene modifications to express IFN-b, IL-2, or IL-12; inhibiting growth of malignant cells through MSC release of
oncolytic viruses (CRAd-MSCs); including caspase-8-dependent apoptosis through TRAIL-expressing MSCs; or bystander killing
through soluble toxic compounds secreted by MSCs expressing pro-toxin converting enzymes, such as HSV-tk, CD, or 5-FC.
Abbreviations: MSCs, mesenchymal stem cells; IFN-b, interferon-beta; IL-2, interlukin-2; IL-12, interlukin-12; CRAd, conditionally
replicating adenoviruses; TRAIL, TNF related apoptosis inducing ligand; HSV-tk, human herpes simplex virus thymidine kinase type 1;
5-FC, 5 flucytosine.
Mesenchymal stem cells 3lungs and abdominal organs within the first 2–3 weeks and
remigration to the lungs in 6–7 weeks. MSCs reduced the pro-
liferative activity of cancer cells in vitro. The mechanism is
thought to be through soluble factors.9
HUCMSC transplantation is expected to become a new
strategy for tumor therapy. The safety profile of hUCMSCs
was satisfactory as well. HUMSCs did not establish colonies
in soft agar and did not exhibit tumorigenic ability after trans-
plantation. Therefore, the use of hUCMSCs in clinical therapy
is safe and feasible.4
3.2. Promotion of tumor growth by MSCs
On the other hand, several studies have documented the tumor
promoting capabilities of MSCs. (Fig. 2).4 This is proposed to
occur through several mechanisms. Rhodes et al.10 showed
that bone marrow hMSCs have the ability to increase tumor
volume, enhance estrogen sensitivity, promote hormone-
independent tumor growth, and alter progesterone receptor
expression. The addition of hMSC increased the estrogen
response by fourfold over that of control tumors.10 Dittmer
et al.3 demonstrated that hMSCs interfere with cell–cell adhe-
sion and enhance migration of breast cancer cells by activating
ADAM10 (a disintegrin and metalloprotease 10), known to
cleave E-cadherin. Recent evidence implies that E-cadherin is
the major protein that mediates MCF-7 cell–cell adhesion in
spheroids.3
The secretion of soluble factors through exosomes is yet
another mechanism by which MSCs promote tumor progres-sion. MSCs were shown to secrete 40–100 nm particles, which
have the typical characteristics of exosomes, and these MSC-
derived exosomes promoted migration of the breast cancer cell
line MCF-7. Global gene expression profiling revealed that
several cancer-related signaling pathways were upregulated
after exosome treatment in MCF7. In addition, the Wnt sig-
naling pathway was further confirmed to be activated. These
findings demonstrated a new mechanism through which
MSC-conditioned media may contribute to tumor cell
migration.11
Furthermore, MSCs were found to promote breast cancer
cell proliferation in vivo. Yan et al. showed that MSCs could
enhance mammosphere formation partially via the epidermal
growth factor (EGF)/epidermal growth factor receptor
(EGFR)/Akt signaling pathway.12
In addition, MSCs may promote breast cancer metastasis
through facilitation of epithelial mesenchymal transition
(EMT).13,14 EMT is a complex series of cellular reprogram-
ming events which culminates in the loss of epithelial charac-
teristics and the de novo acquisition of a mesenchymal
phenotype. During embryonic development, EMT imparts
the plasticity and migratory capabilities that enable the exten-
sive cell movements underlying gastrulation and organogene-
sis.13 It is a critical process underlying the subpopulation of
breast cancer cells that is responsible for tumor initiation
and for regenerating the tumor after initial bulk tumor regres-
sion following therapy.15
The mechanism by which MSCs affect breast cancer cells is
thought to be through soluble factors as bone morphogenetic
Figure 2 Circulation-derived MSCs migrate to tumors and promote cancer progression. MSC niches (depicted here in the bone, but it
could be in other tissues as well) respond to numerous signals generated by the tumor milieu. These signals, including TGF-b, IL-6,
Cyclophilin B, HDGF, uPA/uPAR, MCP-1, VEGF, and FGF2, act as chemoattractants for MSCs. At the tumor site, MSCs infiltrate into
the stroma and produce bioactive molecules such as CCL5, IL-6, SDF-1, and TGF-b, which promote tumour growth and/or distant
metastasis to secondary organs, such as the lungs. Abbreviations: TGF-b, transforming growth factor beta; IL-6, interlukin-6; HDGF,
Hepatoma-Derived Growth Factor; uPA, urokinase-type plasminogen activator; uPAR, urokinase-type plasminogen activator receptor;
MCP-1, monocyte chemoattractant protein-1; VEGF, vascular endothelial growth factor; FGF2, fibroblast growth factor 2; CCL5,
chemokine (C-C motif) ligand 5; SDF-1, stromal cell-derived factor 1.
4 H.A. Shakshouk, H. Rashwanprotein 9 (BMP9). BMP 9 may regulate the cross-talk between
MDA-MB-231 breast cancer cells and HS-5 bone marrow-
derived MSCs in a co-culture system. Wan et al.16 indicated
that BMP 9 can reduce receptor activator of nuclear factor
Kappa B ligand (RANKL) secretion by HS-5 cells and inhibit
the invasion of MDA-MB-231 cells through blocking the AKT
signaling pathway. Simultaneously, BMP 9 can promote the
osteogenic differentiation and proliferation of human bone
marrow stromal cell line HS-5 cells in the tumor
microenvironment.16
In summary, MSCs interact with tumor cells in a myriad of
ways, which have the potential to support or suppress tumor
growth. The heterogeneity in MSCs is likely a major factor
contributing to the inconsistent reports about the effects of
MSCs on tumors. No evidence of tumor formation has been
reported in over 1000 patients treated with MSCs for a variety
of indications, so far.5
The use of hUCMSCs in clinical therapy is expected to be
safe and feasible.4 However, the possibility of MSCs promot-
ing tumor growth and metastasis raises concerns about the
safety of their use as clinical tools.5 Further research in the
field of mesenchymal stem cells and breast cancer is required
before they can be widely used in the treatment of breast
cancer.Conflict of interest
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